Pacifici R, Brown C, Puscheck E, Friedrich E, Slatopolsky E, Maggio D, McCracken R, Avioli L V
Division of Endocrinology and Bone and Mineral Diseases, Jewish Hospital of St. Louis, MO 63110.
Proc Natl Acad Sci U S A. 1991 Jun 15;88(12):5134-8. doi: 10.1073/pnas.88.12.5134.
To determine whether mononuclear cell secretory products contribute to the changes in bone turnover that characterize the development of postmenopausal osteoporosis, we evaluated the effects of oophorectomy and subsequent estrogen replacement on the spontaneous secretion of interleukin 1 (IL-1) and tumor necrosis factor alpha (TNF-alpha) and on the phytohemagglutinin A-induced secretion of granulocyte-macrophage colony-stimulating factor (GM-CSF) from peripheral blood mononuclear cells. In 15 healthy premenopausal women who underwent oophorectomy, increases in GM-CSF activity were observed as early as 1 week after surgery, whereas elevations in IL-1 and TNF-alpha and in hydroxyproline/creatinine and calcium/creatinine ratios, two urinary indices of bone resorption, were detectable 2 weeks after the surgical procedure. Six of the oophorectomized women received no estrogen therapy after surgery and in these subjects hydroxyproline/creatinine and calcium/creatinine ratios plateaued 6 weeks postoperatively, and all three cytokines reached the highest levels 8 weeks after oophorectomy, when the study ended. In the remaining 9 women, who were started on estrogen replacement therapy 4 weeks after oophorectomy, decreases in the indices of bone resorption paralleled decreases in the secretion of the cytokines, with lower levels detected after 2 weeks of therapy. In the women who did not receive estrogen therapy, circulating osteocalcin, a marker of bone formation, increased beyond preoperative levels 8 weeks after oophorectomy, whereas in the estrogen-treated subjects osteocalcin remained unchanged in the entire study period. In 9 female controls who underwent simple hysterectomy, cytokine release and biochemical indices of bone turnover did not change after surgery. These data indicate that changes in estrogen status in vivo are associated with the secretion of mononuclear cell immune factors in vitro and suggest that alterations in the local production of bone-acting cytokines may underlie changes in bone turnover caused by surgically induced menopause and estrogen replacement.
为了确定单核细胞分泌产物是否促成了绝经后骨质疏松症发展过程中所特有的骨转换变化,我们评估了卵巢切除术及随后的雌激素替代疗法对外周血单核细胞白细胞介素1(IL-1)和肿瘤坏死因子α(TNF-α)的自发分泌以及对植物血凝素A诱导的粒细胞-巨噬细胞集落刺激因子(GM-CSF)分泌的影响。在15名接受卵巢切除术的健康绝经前女性中,早在术后1周就观察到GM-CSF活性增加,而IL-1、TNF-α以及骨吸收的两项尿液指标——羟脯氨酸/肌酐和钙/肌酐比值在手术2周后可检测到升高。6名卵巢切除术后的女性术后未接受雌激素治疗,在这些受试者中,羟脯氨酸/肌酐和钙/肌酐比值在术后6周趋于平稳,并且在卵巢切除术后8周(即研究结束时)所有三种细胞因子均达到最高水平。在其余9名女性中,她们在卵巢切除术后4周开始接受雌激素替代疗法,骨吸收指标的下降与细胞因子分泌的减少相平行,治疗2周后检测到较低水平。在未接受雌激素治疗的女性中,骨形成标志物循环骨钙素在卵巢切除术后8周超过术前水平升高,而在接受雌激素治疗的受试者中,骨钙素在整个研究期间保持不变。在9名接受单纯子宫切除术的女性对照中,术后细胞因子释放和骨转换的生化指标未发生变化。这些数据表明,体内雌激素状态的变化与体外单核细胞免疫因子的分泌相关,并提示骨作用细胞因子局部产生的改变可能是手术诱导绝经和雌激素替代所致骨转换变化的基础。